1. Borek DrS, editor. New Visions in Biological Science Vol. 8 [Internet]. Book Publisher International (a part of SCIENCEDOMAIN International); 2022 [cited 2024 Jan 8]. Available from: https://stm.bookpi.org/NVBS-V8/issue/view/520
2.
Cheng Q, Huang J, Xu L, Li Y, Li H, Shen Y, et al. Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression. Int J Neuropsychopharmacol 2020 Mar 25; 23(2): 76-87.
3.
Crupi R, Marino A, Cuzzocrea S. New Therapeutic Strategy for Mood Disorders. Curr Med Chem 2011 Oct 1; 18(28): 4284-98.
4.
Deyama S, Bang E, Wohleb ES, Li XY, Kato T, Gerhard DM, et al. Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine. Am J Psychiatry 2019 May; 176(5): 388-400.
5.
Freudenberg F, Celikel T, Reif A. The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: Central mediators of pathophysiology and antidepressant activity? Neurosci Biobehav Rev 2015 May; 52: 193-206.
6.
Gonda X, Dome P, Neill JC, Tarazi FI. Novel antidepressant drugs: Beyond monoamine targets. CNS Spectr. 2023 Feb; 28(1): 6-15.
7.
Henter ID, Park LT, Zarate CA. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. CNS Drugs 2021 May; 35(5): 527-43.
8.
Iosifescu DV, Jones A, O’Gorman C, Streicher C, Feliz S, Fava M, et al. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). J Clin Psychiatry [Internet]. 2022 May 30 [cited 2024 Mar 27]; 83(4). Available from: https://www.psychiatrist.com/jcp/efficacy-safety-of-axs-05-dextromethorphan-bupropionmdd
9.
Keam SJ. Dextromethorphan/Bupropion: First Approval. CNS Drugs. 2022 Nov; 36(11): 1229-38.
10.
Khabir Y, Hashmi MR, Asghar AA. Rapid-acting oral drug (Auvelity) for major depressive disorder. Ann Med Surg [Internet]. 2022 Oct [cited 2024 Mar 27]; 82. Available from: https://journals.lww.com/10.1016/j.amsu.2022.104629
11.
Krupa AJ, Wojtasik-Bakalarz K, Siwek M. Vortioxetine – pharmacological properties and use in mood disorders. The current state of knowledge. Psychiatr Pol 2023 Dec 31; 57(6): 1109-26.
12.
Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, et al. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol Psychiatry 2017 May; 81(10): 886-97.
13.
Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA. Rapid Onset of Antidepressant Action: A New Paradigm in the Research and Treatment of Major Depressive Disorder. J Clin Psychiatry 2008 Jun 15; 69(6): 946-58.
14.
Machado-Vieira R, Henter ID, Zarate Jr. CA. New targets for rapid antidepressant action. Prog Neurobiol 2017 May; 152: 21-37.
15.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs 2021 Jan 2; 26(1): 63-74.
16.
Malhi GS, Mann JJ. Depression. The Lancet 2018 Nov; 392(10161): 2299-312.
17.
McCarthy B, Bunn H, Santalucia M, Wilmouth C, Muzyk A, Smith CM. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. Clin Psychopharmacol Neurosci 2023 Nov 30; 21(4): 609-16.
18.
McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, Trivedi MH, et al. Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant Medication. J Clin Psychopharmacol 2011 Apr; 31(2): 180-6.
19.
McClure EW, Daniels RN. Classics in Chemical Neuroscience: Dextromethorphan (DXM). ACS Chem Neurosci 2023 Jun 21; 14(12): 2256-70.
20.
Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov 2017 Jul; 16 (7): 472-86.
21.
Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther 2016 Mar; 159: 1-22.
22.
Nicholson KL, Hayes BA, Balster RL. Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 1999 Sep 3; 146(1): 49-59.
23.
Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav 2012 Feb; 100(4): 656-64.
24.
Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010 Jan; 40(1): 41-50.
25.
Rianprakaisang TN, Prather CT, Lin AL, Murray BP, Hendrickson RG, on behalf of the Toxicology Investigators Consortium (ToxIC). Factors associated with seizure development after bupropion overdose: a review of the toxicology investigators consortium. Clin Toxicol 2021 Dec 2; 59(12): 1234-8.
26.
Romanelli F, Smith KM. Dextromethorphan abuse: Clinical effects and management. J Am Pharm Assoc 2009 Mar; 49(2): e20-7.
27.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry 2006 Nov; 163(11): 1905-17.
28.
Shad MU. Recent Developments in Pharmacotherapy of Depression: Bench to Bedside. J Pers Med 2023 Apr 29; 13(5): 773.
29.
Siwek M, Woroń J, Wrzosek A, Gupało J, Chrobak AA. Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs. Front Pharmacol 2023 Sep 27; 14: 1271776.
30.
Smith K. Mental health: A world of depression. Nature 2014 Nov; 515(7526): 180-1.
31.
Stahl SM. Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity. CNS Spectr 2019 Oct; 24(5): 461-6.
32.
Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry 2022 Jul 1; 179(7): 490-9.
33.
Thase ME, Haight BR, Johnson MC, Hunt T, Krishen A, Fleck RJ, et al. A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Sustained-Release Bupropion on Blood Pressure in Individuals With Mild Untreated Hypertension. J Clin Psychopharmacol 2008 Jun; 28(3): 302-7.
34.
Trivedi MH, Daly EJ. Treatment strategies to improve and sustain remission in major depressive disorder. Dialogues Clin Neurosci 2008; 10(4): 377-84.
35.
Woroń J, Siwek M, Gorostowicz A. Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders. Psychiatr Pol 2019 Oct 30; 53(5): 977-95.
